Journal article
Vitamin B6 catabolism and lung cancer risk: Results from the Lung Cancer Cohort Consortium (LC3)
H Zuo, PM Ueland, undefined Midttun, GS Tell, A Fanidi, W Zheng, X Shu, Y Xiang, J Wu, R Prentice, M Pettinger, CA Thomson, GG Giles, A Hodge, Q Cai, WJ Blot, M Johansson, J Hultdin, K Grankvist, VL Stevens Show all
Annals of Oncology | ELSEVIER | Published : 2019
Abstract
Background Increased vitamin B6 catabolism related to inflammation, as measured by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and pyridoxal-5'-phosphate), has been positively associated with lung cancer risk in two prospective European studies. However, the extent to which this association translates to more diverse populations is not known. Materials and methods For this study, we included 5323 incident lung cancer cases and 5323 controls individually matched by age, sex, and smoking status within each of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific odds ratios (ORs) and 95% confidence intervals (CIs) for the association between ..
View full abstractGrants
Awarded by State of Maryland
Funding Acknowledgements
The Lung Cancer Cohort Consortium (LC3) was supported by National Institutes of Health/National Cancer Institute (1U01CA155340-01) and National Health and Medical Research Council, Australia (1050198). The Health Professionals Follow-up Study and Nurses' Health Study were supported by a grant from the National Institutes of Health (NIH) grants UM1CA186107, P50CA127003, P01CA87969, R01CA49449, and UM1 CA167552. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.